Tuesday, November 5, 2024

Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients

Related stories

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci Corporation a data-first generative AI drug creation company, and...

GreyNoise Intelligence Discovers Zero-Day Vulnerabilities in Live Streaming Cameras with the Help of AI

GreyNoise Intelligence, the cybersecurity company providing real-time, verifiable threat...

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Medidata, a Dassault Systèmes brand and leading provider of...

Blend Appoints Mike Mischel as SVP of AI Consulting

Blend, a leader in data science and AI-powered solutions,...

Patronus AI Launches Industry-First Self-Serve API for AI Evaluation and Guardrails

Patronus AI announced the launch of the Patronus API, the first...
spot_imgspot_img

Acquisition of MotionHall reinforces strategy to lead market-specific solutions, including workflows and expert services fuelled by industry vertical AI

Clarivate Plc a leading global provider of transformative intelligence, has announced an agreement to acquire the substantial majority of assets of MotionHall, a Silicon Valley technology start-up company serving the life sciences with industry vertical artificial intelligence (AI) solutions. The asset purchase serves as a key component of the Clarivate™ Life Sciences & Healthcare strategy to deliver transformative intelligence through the application of generative AI (GenAI) and proprietary industry vertical AI solutions. Clarivate provides people and organizations with transformative intelligence they can trust, propelling human ingenuity into our world’s greatest breakthroughs.

The acquisition of the full intellectual property, clients and team from MotionHall enables acceleration of multiple roadmaps, including targeted enhancements to Clarivate Cortellis™, market assessments, as well as a new Business Development & Licensing Enterprise Workbench.

Also Read: IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Henry Levy, President, Life Sciences & Healthcare, Clarivate said: “As part of our strategy, Clarivate will enhance existing products and introduce novel solutions utilizing AI, to streamline clients’ workflows and accelerate speed to insight and action. Concurrent with this transaction, the team from MotionHall has joined Clarivate to progress our on-going commitment to provide exceptional value for our clients across the entire drug, device and medical technology lifecycle.”

Rachael Craig, SVP and Managing Director, Life Sciences & Healthcare Strategy Products, Clarivate, said: “Clarivate is well positioned to become a leading industry vertical artificial intelligence (AI) player. Your healthier tomorrow is being built through the successful combination of deep life sciences industry expertise and mastery of frontier AI capabilities. Clients who choose Clarivate as we advance industry vertical AI together, will have access to this frontier, becoming better equipped to deliver outcomes for their company and patients that meet today’s complex challenges.”

In the near-term, Clarivate will leverage MotionHall IP to further enhance Cortellis search, as well as scope of data quality and coverage.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img